Healio

•

Channel • 10 Shows

Medicine

Medicine

Every two months
Medicine

Medicine

Every two months
Medicine

Medicine

Monthly
Medicine

Medicine

Twice monthly
Medicine

Medicine

Monthly
Medicine

Medicine

Updated 10/05/2022
Medicine

Medicine

Updated 24/01/2022

3 days ago

Incorporating, retaining advanced practice providers in GI practice

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. · How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 · How can we effectively onboard APPs? 10:24 · Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 · What models have worked well for deploying APPs into GI practices? 24:32 · What strategies are most effective for APP retention? 29:07 · How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc. Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.
29 May

GCA mimics: How to spot them, a case-based discussion with Dr. Leonard H. Calabrese, DO

Not all jaw claudication is giant cell arteritis. Hear some interesting cases and learn about things to look for in the labs to suspect an alternative diagnosis along with co-host Leonard H. Calabrese, DO. · When GCA isn't GCA, walking through mimic cases 2:43 · Infectious mimics 14:36 · Large vessel involvement cases 16:47 · GCA as a medical emergency 22:05 · Erdheim-Chester disease 23:40 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
28 Apr

Bats, boats, baths, and vasculitis: The story of ultrasound in GCA

In this week's episode we interview Kinanah Yaseen, MD, a rheumatologist from Cleveland Clinic's department of rheumatic and immunologic diseases about using ultrasound for giant cell arteritis. · Intro by Adam J. Brown, MD 0:12 · Dr. Brown's recent patient 1:34 · History of ultrasound and GCA 3:20 · Episode overview 7:05 · History of echolocation; how bats helped us invent ultrasound 8:00 · What is a bat bomb? 14:56 · How the Titanic helped us invent ultrasound 16:48 · Neurologists bring ultrasound to medicine 20:09 · OB/GYN is next to use ultrasound 23:11 · Ultrasound image quality becomes better 26:32 · Ultrasound use in giant cell arteritis 28:44 · Welcome Kinanah Yaseen, MD 33:49 · Using ultrasound in the clinic 34:25 · Can you walk us through an ultrasound of the axillary and vertebral arteries? 37:16 · Can you tell us why we stopped looking for sites to biopsy by finding narrowing of the vessels? 38:19 · Tell us about the halo sign 39:10 · How do you validate your ultrasound skills? 40:20 · If we start a patient on steroids, how useful is an ultrasound? 42:35 · Episode summary 44:20 · Thank you for listening 45:57 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Kinanah Yaseen, MD, is a is a staff member of Cleveland Clinic's department of rheumatic and immunologic diseases. References: Friedman, G, et al.Isr J Med Sci. 1988 Kaproth-Joslin K A, et al. Radiographics. 2015 ;doi:10.1148/rg.2015140300 Puéchal X, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)92626-7 Schmidt W A, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)93005-1 Sigel B. Ultrasound Med Biol. 1998;doi:10.1016/s0301-5629(97)00264-0 Editor's Note: This has been updated to include references.
30 Jun

Green goo and glucose: Pleural effusions in rheumatoid arthritis

In this episode of Rheuminations, host Adam J. Brown, MD, will walk you through the history of pleural effusions in rheumatoid arthritis. He discusses topics ranging from fascinating case studies to how pleural effusions are treated today. · Diving into pleural effusions. 2:38 · What's in the fluid? 12:01 · When did pleural effusions become linked to RA? 15:18 · The glucose talk. 27:04 · Green effusions. 32:40 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
04/05/2021

VEXAS

In this episode, I interview the NIH team who brought you VEXAS! Hear different points of view of this disease, how it was discovered, clinical presentations, as well as where this research could lead. Then, we wrap up with Dr. Kastner's historical take on autoinflammatory disorders! Intro :11 In this episode :12 Big thanks to Peter Grayson, MD, MSc 2:07 About our guests 2:30 The interview 5:10 How did VEXAS come about? 5:37 You had an idea of where to start looking? 6:58 What should rheumatologists know about 'somatic mutation'? 12:31 Do you think this could be a clue to other conditions? 13:37 Can you tell us about some of the unique aspects that we see in these patients with MDS that make them atypical? 17:14 How's the clinician going to see or note the vacuoles? 18:53 Do we have kind of a pathway for how the vacuoles are forming based on what we know about ubiquitization or is that unclear? 20:51 What's going to raise the antenna that this isn't "run of the mill x disease"? 23:33 How, in your experience, have patients responded to diagnoses being changed? 37:15 Where does everyone see the therapy going for this condition in the future? 41:15 Do we think that with this approach that this is going to "reshuffle the deck" of what we call certain diseases from multiple different specialties over the next decade? 44:02 Would you mind walking us through a little bit about FMF and how the different variants you saw led to further discoveries? 49:46 What was known about IL1 at the time? How did that knowledge of IL1 come along? 52:53 It's such a true honor to have you all on 57:42 David Beck, MD, PhD, is a genetics fellow at the NIH. He can be reached at david.beck@nih.gov. Marcella A. Ferrada, MD, is Lawrence Shulman scholar at NIAMS. She can be reached at ferradama@mail.nih.gov. Peter Grayson, MD, MSc, is head of the Vasculitis Translational Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and associate director of the NIAMS fellowship program. He can be reached at peter.grayson@nih.gov. Dan Kastner, MD, PhD, is an NIH distinguished investigator in the Metabolic, Cardiovascular and Inflammatory Disease Genomics Branch; director in the Division of Intramural Research; and head of the Inflammatory Skin Disease Section at the National Human Genome Research Institute. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum Disclosures: Beck, Brown, Ferrada, Grayson and Kastner report no relevant financial disclosures.
24 Mar

ILD for the rheumatologist: Digging through the past and making sense of the present

In this week's episode we interview Joseph Parambil, MD, staff member in the department of pulmonary, allergy and critical care medicine at Cleveland Clinic, about the current challenges of interstitial lung disease, or ILD. · Intro by Adam J. Brown, MD 0:12 · Welcome back Joseph Parambil, MD 0:32 · But first, some medical history on ILD 1:04 · ILD vs. IPF 2:26 · A quick aside into silicosis and bleomycin 4:27 · Trying to describe pulmonary fibrosis 5:23 · The different types of ILD 9:44 · Finding a slow progression of disease and autoimmune conditions 10:59 · Pulmonary fibrosis diagnoses in 1963 14:41 · The modern era of ILD 16:22 · Nonspecific interstitial pneumonia 20:12 · Handing things over to Dr. Parambil 23:01 · Helping rheumatologists understand ILD/The alphabet soup 24:34 · The shift from biopsies and using immunosuppression 33:07 · Is the workup similar for UIP and NSIP? 35:26 · Is there a standard protocol for workup in terms of serologies? 36:30 · The danger of choosing the wrong treatment 38:43 · Immunosuppression in patients with pulmonary hypertension and ILD 40:52 · UIP and ANCA vasculitis 42:12 · Compared to ten years ago, how are we doing with treatments? 43:10 · Where are we with lung transplants? 50:49 · Looking at hematopoietic stem cell transplants 53:24 · The importance of early diagnosis 54:14 · Antifibrotic medicines 56:15 · Chronic and acute interstitial lung diseases 58:41 · Thank you, Dr. Parambil 1:03:54 · A conclusion from Dr. Brown 1:04:20 · Thank you for listening 1:04:55 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Joseph Parambil, MD, is a staff member in the Respiratory Institute and the director of the HHT Center of Excellence and the Vascular Anomalies Center at the Cleveland Clinic. He is associate professor of medicine at Cleveland Clinic's Lerner College of Medicine. He is certified by the American Board of Internal Medicine with additional specialty certification in pulmonary medicine and critical care medicine. References: Homolka J. CMAJ. 1987;PMID:3315158 Liebow A, et al. : "Frontiers of Pulmonary Radiology." The interstitial pneumonias, pp. 102-141. 1969. Grune & Stratton. Liebow A, et al. Calif Med. 1969;PMID:PMC1501512 Noble PW, et al. Am J Respir Cell Mol Biol. 2005;doi:10.1165/rcmb.F301 Scadding JG, et al. Thorax. 1967;doi:10.1136/thx.22.4.291 Disclosures: Brown and Parambil report no relevant financial disclosures.
20/05/2022

SAPHO Part 1

What is SAPHO? What does the 'H' stand for, again? This episode explores some basics about the condition and delves into the history of how this disease came to be. Intro :01 Welcome to another exciting episode of Rheuminations :11 About today's episode :17 What does the acronym 'SAPHO' stand for? :37 How do you define this condition? 2:35 So, what is SAPHO syndrome? 4:59 Are any of the letters specific for SAPHO syndrome? 15:20 How the puzzle pieces were put together 15:48 Over the next ensuing decades, when did we start realizing that patients could have dermatologic manifestations? 23:00 So, what about hyperostosis? 30:46 Why isn't the Sonozaki group getting the credit? 39:22 So, how did we get SAPHO? 40:26 How did they get 85 patients? 42:50 We went through a lot in this paper 45:29 Next episode preview 46:29 Thanks for listening 47:03 Disclosure: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum and be sure to check out Rheum + Boards – your destination for rheumatology education and quizzes! References: Chamot AM, et al. Rev Rheum Mal Osteoartic. 1987;54:187-196. Giedion A, et al. Ann Radiol (Paris) 1972;15:329-342. Köhler H, et al. Ann Intern Med. 1977;87:192-194. Nguyen MT, et al. Semin Arthritis Rheum. 2012;42:254-265. Raposo I, Torres T. Am J Clin Dermatol. 2016;17:349-358. Romani M, et al. Clin Podiatr Med Surg. 2021;38:541-552. Sonozaki H, et al. Ann Rheum Dis. 1981;40:547-553. Windom RE, et al. Arthritis Rheum. 1961;4:632-635.
22 May

An overview of Rome V

In this episode, Lin Chang, MD, and Jan Tack, MD, PhD, discuss the history and evolution of Rome criteria, developing guidelines for multifactorial disorders in Rome V and more. · Lin Chang, MD, and Jan Tack, MD, PhD 1:04 · How has the Rome Foundation evolved over the last ten years? 4:26 · What are the Rome criteria, and why should clinicians care about them? 7:20 · How did these guidelines become the Rome criteria? 10:32 · What is the timeline of developing these criteria? 12:35 · Can you tell us about how the Rome Foundation got to the name "DGBI", and why it makes sense for multifactorial conditions? 22:22 · What are the highlights and most important changes from Rome V? 26:38 · How will this information be disseminated so clinicians can learn about it? 34:22 · What lessons did you learn from the Rome V process? 37:40 · What's next for the Rome Foundation? 40:04 Lin Chang, MD, is professor of medicine and vice chief of the Vatche and Tamar Manoukian Division of Digestive Diseases at David Geffen School of Medicine at UCLA. Jan Tack, MD, PhD, is president of the Rome Foundation. He also serves as professor of medicine at KU Leuven and chief of the division of gastroenterology and hepatology at Leuven University Hospitals. We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro @sameerkberry @umfoodoc. Disclosures: Chey and Tack report no financial disclosures. Chang reports consulting roles with Ardelyx, Atmo, Eli Lilly & Co., FoodMarble, GSK, Ironwood Pharmaceuticals and Ono Pharmaceutical; speaking fees from Bausch Health; research grants from AnX Robotica and Ironwood; serving on the Rome Foundation Board of Directors; and having unvested stock options with FoodMarble, ModifyHealth, PICO Health and Trellus Health. Reference: · Drossman DA, et al. Gastroenterology. 2026;doi:10.1053.j.gastro.2026.02.014.
22/01/2025

COVID's role in autoimmunity and where we are in the world of long COVID

On this episode, hear the 2024 updates on COVID-19, long COVID and the latest developments in research in rheumatology. Hosted by Dr. Leonard Calabrese. Intro 0:12 In this episode 0:21 Coming up on Healio Rheuminations 0:56 COVID-19, long COVID and the rheumatologist with Leonard Calabrese, DO 2:19 Questions 3:12 Long COVID 4:46 Calabrese's bias 10:15 The evidence 13:08 Auto antibodies 14:54 Why does the body develop auto antibodies? 17:47 COVID-19 and epidemiologic association 22:25 New clinical entity 26:40 Therapeutic implications 31:00 In conclusion 32:00 Thanks for listening 33:18 Leonard H. Calabrese, DO, is the chief medical editor, Healio Rheumatology, and professor of medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland Clinic. Disclosures: Calabrese reports professional relationships with AbbVie, AstraZeneca, Bristol Myers Squibb, Galvani, Genentech, GlaxoSmithKline, Janssen, Novartis, Regeneron, Sanofi and UCB. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum.
31/01/2023

Vascular Ehlers-Danlos Syndrome, Part 1

Dive into vascular Ehlers-Danlos syndrome. What is it? How does it present? Get clues to its diagnosis and learn more about collagen than you ever wanted to know. Intro 0:12 In this episode 0:17 Why vascular Ehlers-Danlos syndrome? 0:28 Case study: Dr. Mories 2:20 What can we learn about vascular Ehlers-Danlos syndrome? 05:02 Collagen and elastin 05:57 Collagen: horses and glue 07:07 More about collagen 10:35 Why is it a problem to miss a little bit of collagen? 14:14 The problem in vascular Ehlers-Danlos syndrome 15:06 The history of vascular EDS 15:41 How is vascular Ehlers-Danlos syndrome diagnosed? 16:36 A vascular Ehlers-Danlos syndrome diagnosis 22:33 Mouse models 23:29 Clinical and genetic features of vascular Ehlers-Danlos syndrome 24:39 Question of vasculitis 25:55 The skin: the most common symptom of vascular EDS 28:00 Family history, de novo mutations and pregnancy 29:43 Surgery or vascular intervention 31:39 How do patients do in the long-term? 32:54 Summary 34:00 Preview of part 2 35:42 Thanks 36:25 Disclosures: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Barabas AP. J Cardiovasc Surg (Torino). 1972;13(2):160-7. Chow MJ, et al. Biophys J. 2014;doi:10.1016/j.bpj.2014.05.014. Liu X, et al. Proc Natl Acad Sci USA. 1997;doi:10.1073/pnas.94.5.1852. Mories A. Scott Med J. 1960;5:269-72. Pepin M, et al. N Engl J Med. 2000;doi:10.1056/NEJM200003093421001. Pepin MG, et al. Genet Med. 2014;doi:10.1038/gim.2014.72. Piez KA. Matrix Biol. 1997;doi:10.1016/s0945-053x(97)90037-8. Pope FM, et al. Proc Natl Acad Sci USA. 1975;doi:10.1073/pnas.72.4.1314. Wagenseil JE, et al. J Cardiovasc Transl Res. 2012;doi:10.1007/s12265-012-9349-8. Zilocchi M, et al. AJR Am J Roentgenol. 2007;doi:10.2214/AJR.07.2370.

The content you need, when you need it.